Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review
Patients with chronic liver disease are often diagnosed during an index presentation to hospital with decompensated cirrhosis or liver-related events, and these presentations are associated with high mortality. However, there is often a long asymptomatic phase, in which there is an opportunity for earlier diagnosis and interventions to prevent progression to advanced disease. Therefore, strategies for early diagnosis and interventions (including behavioural changes and pharmacological treatments) that prevent patients progressing to cirrhosis and its associated complications probably have substantial benefits for patients and health-care services. Many community pathways have been generated. Some pathways focus on abnormal liver function tests as a starting point to diagnose liver disease. Other pathways target groups at greater risk of chronic liver disease—particularly people with harmful alcohol consumption, type 2 diabetes, and obesity. This systematic review summarises the existing strategies available for the early detection or risk stratification of liver disease, focusing primarily on alcohol-related liver disease and non-alcoholic fatty liver disease. Conducting randomised clinical trials that compare different strategies will be essential to elucidate which pathways are acceptable to patients, feasible, provide high diagnostic accuracy for the detection of liver disease, improve liver-related outcomes, and are most cost-effective at the population level.
770-780
Abeysekera, K.W.M.
41123f6d-f0e4-42b5-bc69-1da3c762170e
Macpherson, I.
5726c3da-f04e-4ff3-a59a-ba25803de3d5
Glyn-Owen, K.
046b9ac1-ab79-4786-af26-f1a2f96ddc05
McPherson, S.
e5101fdd-1ca4-4864-b603-5ea0a2363f11
Parker, R.
094574ff-6ea4-4b37-95f4-cd6598ba860d
Harris, R.
8cc2fa3d-aab1-4fb4-b0b8-ad516cf5a08b
Yeoman, A.
09ac1b35-ad38-430e-9913-3be7d1f0b0fe
Rowe, I.A.
fa6c6f89-6cff-4eed-9e84-44f4cb9f0be7
Dillon, J.F.
f406e30a-3ad4-4a53-80db-6694bab5e3ed
1 August 2022
Abeysekera, K.W.M.
41123f6d-f0e4-42b5-bc69-1da3c762170e
Macpherson, I.
5726c3da-f04e-4ff3-a59a-ba25803de3d5
Glyn-Owen, K.
046b9ac1-ab79-4786-af26-f1a2f96ddc05
McPherson, S.
e5101fdd-1ca4-4864-b603-5ea0a2363f11
Parker, R.
094574ff-6ea4-4b37-95f4-cd6598ba860d
Harris, R.
8cc2fa3d-aab1-4fb4-b0b8-ad516cf5a08b
Yeoman, A.
09ac1b35-ad38-430e-9913-3be7d1f0b0fe
Rowe, I.A.
fa6c6f89-6cff-4eed-9e84-44f4cb9f0be7
Dillon, J.F.
f406e30a-3ad4-4a53-80db-6694bab5e3ed
Abeysekera, K.W.M., Macpherson, I., Glyn-Owen, K., McPherson, S., Parker, R., Harris, R., Yeoman, A., Rowe, I.A. and Dillon, J.F.
(2022)
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review.
The Lancet Gastroenterology & Hepatology, 7 (8), .
(doi:10.1016/S2468-1253(22)00020-6).
Abstract
Patients with chronic liver disease are often diagnosed during an index presentation to hospital with decompensated cirrhosis or liver-related events, and these presentations are associated with high mortality. However, there is often a long asymptomatic phase, in which there is an opportunity for earlier diagnosis and interventions to prevent progression to advanced disease. Therefore, strategies for early diagnosis and interventions (including behavioural changes and pharmacological treatments) that prevent patients progressing to cirrhosis and its associated complications probably have substantial benefits for patients and health-care services. Many community pathways have been generated. Some pathways focus on abnormal liver function tests as a starting point to diagnose liver disease. Other pathways target groups at greater risk of chronic liver disease—particularly people with harmful alcohol consumption, type 2 diabetes, and obesity. This systematic review summarises the existing strategies available for the early detection or risk stratification of liver disease, focusing primarily on alcohol-related liver disease and non-alcoholic fatty liver disease. Conducting randomised clinical trials that compare different strategies will be essential to elucidate which pathways are acceptable to patients, feasible, provide high diagnostic accuracy for the detection of liver disease, improve liver-related outcomes, and are most cost-effective at the population level.
This record has no associated files available for download.
More information
Published date: 1 August 2022
Identifiers
Local EPrints ID: 501837
URI: http://eprints.soton.ac.uk/id/eprint/501837
ISSN: 2468-1253
PURE UUID: 1a3b7018-0f95-4295-94a5-89067e55e76e
Catalogue record
Date deposited: 10 Jun 2025 18:29
Last modified: 14 Jun 2025 02:23
Export record
Altmetrics
Contributors
Author:
K.W.M. Abeysekera
Author:
I. Macpherson
Author:
K. Glyn-Owen
Author:
S. McPherson
Author:
R. Parker
Author:
R. Harris
Author:
A. Yeoman
Author:
I.A. Rowe
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics